Latest Maraviroc Stories

2009-04-16 06:01:00

- Creates a new focused HIV business with the independence and sustainability to deliver significant improvements in treatment, access and shareholder value - Renews focus on HIV with industry-leading pipeline to deliver more new HIV treatments - Equity split of 85% GSK and 15% Pfizer LONDON and PHILADELPHIA, April 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) and Pfizer Inc (NYSE: PFE) today announced they have entered into an agreement to create a new world-leading HIV...

2008-10-26 12:00:20

Patients taking Selzentry, in combination with Combivir(R) (zidovudine/lamivudine) and selected by an enhanced sensitivity tropism test to screen patients, experienced a 68 percent rate of virologic suppression to undetectable levels, according to the MERIT ES (Reanalysis of the MERIT Study with the Enhanced Trofile Assay) reanalysis presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC(TM))/ 46th Annual Meeting of the Infectious Diseases Society...

2008-10-26 12:00:20

SOUTH SAN FRANCISCO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. announced today that data presented this week demonstrated that in Pfizer Inc's phase III trial of Selzentry(TM) (maraviroc) in treatment naive individuals with CCR5-tropic HIV-1, increased efficacy was shown as a result of the enrichment of the patient population by use of the enhanced version of Monogram's Trofile(TM) Assay. The data were reported this week at the 48th Annual Interscience...

2008-08-20 09:01:30

SOUTH SAN FRANCISCO, Calif., Aug. 20 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. today announced that Wellpoint, Inc. has established a national Medical Policy Guideline for Monogram's Trofile Assay. Wellpoint's guidelines provide that HIV tropism testing with Trofile is considered medically necessary for selecting individuals for treatment with CCR5 antagonists (i.e. Selzentry(TM)) for patients who have experienced virologic failure during antiretroviral treatment regimens and...

2008-06-16 06:00:38

SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. today announced that data related to the enhanced performance of the company's HIV tropism assay were presented in an oral presentation at the 17th International HIV Drug Resistance Workshop in Sitges, Spain. Trofile was introduced commercially upon FDA approval of Selzentry(TM) (maraviroc), Pfizer's first in class CCR5 antagonist, in August 2007. Recent enhancements to Monogram's Trofile(TM) HIV...

2005-09-19 03:40:00

LONDON -- GlaxoSmithKline Plc has suffered a setback in the race to develop a new kind of AIDS pill, following two cases of serious liver problems in patients taking its experimental drug aplaviroc. As a result, the world's largest maker of HIV/AIDS drugs has terminated Phase III tests of the product on so-called "treatment-naive" patients, who have not received other HIV therapies. The news was communicated to the HIV patient community in a statement late last week. Aplaviroc, or GSK 873140,...

Word of the Day
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'